United Kingdom· GB-APID-38372611000001107
Gazyvaro 1000mg/40ml concentrate for solution for infusion vials
A obinutuzumab product containing obinutuzumab, registered in United Kingdom by Originalis B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Obinutuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FA03 (obinutuzumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Obinutuzumab · ATC L01FA03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of obinutuzumab costs, country by country.
Normalised to the WHO defined daily dose (35.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Obinutuzumab · price per daily dose (35.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$143.26
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Obinutuzumab
- Manufacturer
- Originalis B.V.
- Country
- United Kingdom (GB)
- ATC code
- L01FA03
- ATC class
- Obinutuzumab
- Defined daily dose
- 35.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin08719923005093
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
72 interactions on record for obinutuzumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Obinutuzumab · interactions on record
72 records
- 29 severe
- 43 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Obinutuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandGazyvaroOrifarm Oy
- SpainGAZYVARO 1000 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- SwitzerlandGazyvaro
- CzechiaGAZYVARORoche Registration GmbH, Grenzach-Wyhlen
- FranceGAZYVARO 1000 mg, solution à diluer pour perfusionROCHE REGISTRATION (ALLEMAGNE)
- IrelandGazyvaro 1,000 mg concentrate for solution for infusionRoche Registration GmbH
- IcelandGazyvaroRoche Registration GmbH*
- Japanオビヌツズマブ（遺伝子組換え）中外製薬
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Gazyvaro
- Liechtenstein · Gazyvaro
- Norway · Gazyvaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/71273a3f-bc10-493f-93ae-86f19a832222 GET /v1/drugs/71273a3f-bc10-493f-93ae-86f19a832222?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38372611000001107",
"desc": "Gazyvaro 1000mg/40ml concentrate for solution for infusion vials (Originalis B.V.)",
"form": "Solution for infusion",
"vpid": "25503511000001103",
"source": "dmd",
"vtm_id": "776961005",
"strength": "25 mg",
"substance": "Obinutuzumab",
"ingredient": "Obinutuzumab",
"supplier_code": "36751511000001108"
}See everything about obinutuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.